MilliporeSigma, the life science business of Merck KGaA, has expanded its biodevelopment centers for its portfolio of bioprocessing products, manufacturing capabilities, and technological expertise. The expansion includes the opening of…
Lilly Announces Changes in Commercial Organization and Leadership
Eli Lilly and Company has made a series of changes to its commercial organization and leadership structure. The moves come as David A. Ricks assumed the role of president and…
Recipharm Gets OK for Kemwell Indian Biz Acquisition
Recipharm, a contract development and manufacturing organization (CDMO) based in Jordbro, Sweden, has received approval from the Indian Foreign Investment Promotion Board for its proposed acquisition of Kemwell’s Indian operations.…
Sanofi, BI Close on Multi-Billion Dollar Business Swap
Sanofi and Boehringer Ingelheim (BI) have closed on their previously announced multi-billion dollar business-swap transaction signed in June 2016 in most markets on January 1, 2017. The transaction consists of an exchange…
Sanofi, Merck & Co. End Joint European Vaccine Business
Sanofi and its vaccines global business unit, Sanofi Pasteur, have confirmed that they ended their vaccine joint-venture, Sanofi Pasteur MSD (SPMSD), with Merck & Co., known as MSD outside of…
Impax CEO Departs, Board Searches for New Executive
Impax Laboratories, a Hayward, California-based specialty pharmaceutical company focused on controlled-release and specialty generics, has appointed J. Kevin Buchi as interim president and chief executive officer (CEO) following the departure…
GSK Ends Pact, Divests Thrombosis Business to Aspen
GlaxoSmithKline (GSK) has terminated its collaboration in Sub-Saharan Africa with Aspen Pharmacare Holdings, a pharmaceutical company based in KwaZulu-Natal, South Africa, and certain of Aspen’s subsidiaries, in one of a…
Genentech, a member of the Roche Group, has appointed Bill Anderson to chief executive officer, effective January 1, 2017. Mr. Anderson, who is also the head of North American commercial…
Bristol-Myers Squibb’s (BMS’) board of directors has appointed Giovanni Caforio, MD, as chairman of the board, effective May 2, 2017. Caforio, who will continue to serve as chief executive officer…
Biogen’s board of directors has appointed Michel Vounatsos as chief executive officer and member of the board of directors, effective January 6, 2017. Vounatsos previously held the position of executive…